Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors
- PMID: 12476614
Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors
Abstract
Vascular endothelial growth factor (VEGF) is one of the factors related to angiogenesis of tumors and physiological and pathological proliferative processes. Location of VEGF in human thyroid tissue with various thyroid disorders was studied in order to explore its possible involvement in proliferative processes. Immunohistochemical examination was performed on 69 formalin-fixed, paraffin-embedded thyroid tissue specimens using the labelled streptavidin biotin peroxidase complex detection system. VEGF was not identified in normal thyroid follicular cells. Some but not all tumor thyreocytes expressed VEGF in cytoplasm. VEGF positive expression was found in 6/15 patients with papillary carcinoma, 4/9 with follicular carcinoma, 14/28 with follicular adenoma and 2/17 with adenomatous goiter. In benign follicular adenoma and adenomatous goiter the weak expression of VEGF was found in small areas of the tumor tissues, whereas in malignant tumors it was found strongly in many cells. VEGF probably functions as a hypoxia-inducible angiogenic factor, and the expression of VEGF is stronger in malignant tumors, which need more oxygen supply to proliferate. An intensive VEGF production by differentiated thyroid carcinomas could be a promising marker of tumor aggressiveness and may also be useful as a predictor of metastatic potential and extension of tumor mass.
Similar articles
-
Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.World J Surg. 2001 Mar;25(3):302-6. doi: 10.1007/s002680020085. World J Surg. 2001. PMID: 11343180
-
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339. J Pathol. 2003. PMID: 12754739
-
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.Anticancer Res. 2002 Nov-Dec;22(6C):3977-84. Anticancer Res. 2002. PMID: 12553021
-
Angiogenesis in endocrine glands: special reference to the expression of vascular endothelial growth factor.Microsc Res Tech. 2003 Feb 1;60(2):181-5. doi: 10.1002/jemt.10256. Microsc Res Tech. 2003. PMID: 12539172 Review.
-
Angiogenesis in the thyroid gland.J Endocrinol. 2000 Sep;166(3):475-80. doi: 10.1677/joe.0.1660475. J Endocrinol. 2000. PMID: 11029748 Review.
Cited by
-
The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.Eur J Endocrinol. 2007 Oct;157(4):521-7. doi: 10.1530/EJE-07-0252. Eur J Endocrinol. 2007. PMID: 17893268
-
Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).Tumour Biol. 2014 Jul;35(7):6521-9. doi: 10.1007/s13277-014-1868-2. Epub 2014 Apr 1. Tumour Biol. 2014. PMID: 24687553
-
Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma.Clin Exp Med. 2009 Sep;9(3):207-13. doi: 10.1007/s10238-009-0031-7. Epub 2009 Feb 10. Clin Exp Med. 2009. PMID: 19205619
-
Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer.Cancers (Basel). 2021 Jun 3;13(11):2775. doi: 10.3390/cancers13112775. Cancers (Basel). 2021. PMID: 34204889 Free PMC article. Review.
-
[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.Mol Imaging Biol. 2023 Jun;25(3):483-494. doi: 10.1007/s11307-022-01776-4. Epub 2022 Oct 17. Mol Imaging Biol. 2023. PMID: 36253663 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical